Allogene Therapeutics, Inc. (ALLO) AI Stock Analysis

Allogene Therapeutics, Inc., based in South San Francisco, California, focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. Its pipeline centers on UCART19 for relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia. The company is also advancing ALLO-501 in Phase I clinical trials for relapsed or refractory non-Hodgkin lymphoma and ALLO-501A in Phase I/II trials for large B-cell lymphoma and transformed follicular lymphoma. Other clinical candidates include ALLO-715 and ALLO-605 for multiple myeloma, along with ALLO-647. Allogene maintains strategic collaborations with Pfizer Inc., Servier, Cellectis S.A., Notch Therapeutics Inc., and The University of Texas MD Anderson Cancer Center.

Allogene's annual revenue dropped from $38.3M in FY2020 and $38.5M in FY2021 to $243,000 in FY2022, $95,000 in FY2023, and $22,000 in FY2024, reflecting a 4-year revenue CAGR of -84.5%. Research and development expense totaled $192.3M in FY2024, contributing to net income of -$257.6M and an operating margin of -1241813.6%. Across the trailing twelve months, revenue reached $4.6M with an operating margin of -1011.2% and diluted earnings per share of -$0.66. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 100.0% year-over-year.

As of June 30, 2026, Allogene held cash and short-term investments of $332.6M against total debt of $70.4M, resulting in net cash of $262.3M. Total assets stood at $550.1M and shareholders' equity was $436.2M, with a current ratio of 10.72 and a debt-to-equity ratio of 0.16. In FY2024, operating cash flow was -$200.3M and free cash flow was -$201.0M. For FY2025, capital expenditures were $386,000, while share issuance brought in $895,000 following a 5-year share count change of 136.3%.

Allogene holds a market cap of $452.6M and an enterprise value of $316.4M. Its price-to-sales multiple is 97.5x and enterprise value-to-revenue is 68.2x, substantially above the median of its US-listed Healthcare peers of 4.1x. Its price-to-book ratio is 1.3x. In the market, ALLO stock traded at $1.31 as of October 16, 2026, standing 34.3% below its 200-day average. Over the past year, the shares gained 3.1% compared to a 16.8% return for the S&P 500 (SPY), while over five years, the stock dropped 92.1% against an 83.0% gain for the benchmark.

Wall Street sentiment includes 8 Strong Buy, 3 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $9.00 indicates a 587.0% premium over the last close of $1.31. For the current fiscal year ending December 31, 2026, analysts expect an EPS estimate of -$0.59 on revenue of $3.4M. For next fiscal year, 5 analysts project revenue of $12.1M and an EPS estimate of -$0.62. The company beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 5, 2026.

This page is an AI-written research summary of Allogene Therapeutics, Inc. (ALLO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALLO income statement, ALLO balance sheet, ALLO key metrics, ALLO analyst forecast, ALLO chart. See the ALLO stock overview for the latest quote and news.